Clinical trial

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

NCT02099110

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-04-22

PhasePHASE3

Study timeline

Study start (actual)2014-04-22Date precision: day

Registry last updated2018-09-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

Matching Placebo to Ertugliflozin 5 mgDRUG

Matching Placebo to Ertugliflozin 10 mgDRUG

Matching Placebo to sitagliptin 100 mgDRUG

Ertugliflozin 5 mgDRUG · verified · RxNorm: ertugliflozin 5 MG

Ertugliflozin 10 mgDRUG

Sitagliptin 100 mgDRUG · verified · RxNorm: sitagliptin 100 MG

Metformin >= 1500 mg/dayDRUG

Insulin Glargine Rescue MedicationBIOLOGICAL

Glimepiride Rescue MedicationDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Pfizercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02099110 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.